Please login to the form below

Not currently logged in
Email:
Password:

EMA drug communication reviewed

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report.

The report represents the outcome of a year-long project carried out by Dr Frederic Bouder, from Maatstricht University, on the invitation of the agency.

Dr Bouder carried out a detailed analysis of the expectations and attitudes of the agency's stakeholders towards its communication on medicines.

He recommended that the agency set up a risk communication advisory board, form a strategic view on transparency, involve patients in communication activities on a routine basis, and review the format and timing of its communication vehicles.

The EMA has started implementing some of Dr Bouder's suggestions. It is also considering his recommendations during the implementation of the new pharmacovigilance legislation.

The EMA has the report available to download (PDF).

1st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics